Experimental evidence suggests that rheumatoid synovitis may be perpetuated by the generation of reactive oxygen species during hypoxic reperfusion injury. The latter occurs because increased intra-articular pressure during exercise exceeds synovial capillary perfusion pressure, impairing blood flow. The object of this study was to establish a marker for and the mechanism of synovial hypoxic reperfusion injury.
incubated at 60°C for 30 minutes and applied to an agarose gel with a 13 mm stacking zone (0-8% agarose in 0-125 M TRIS HCI with 0-1% sodium dodecyl sulphate, pH 6-8) and a 37 mm separation zone (0-8% agarose in 0 5 M TRIS HCI with 0-1% sodium dodecyl sulphate, pH 8 8) . After electrophoresis and blotting onto a nitrocellulose membrane the latter was placed in a blocking solution (5% dried milk) for one hour, washed three times with 0-1% Tween 20 in borate buffered saline and incubated at room temperature with rabbit antihuman vWF diluted 1:750 in borate buffered saline. After three washes with 0-1% Tween 20 in borate buffered saline an alkaline phosphatase conjugated swine antirabbit antibody (Dako) diluted 1:750 in borate buffered saline was added. Following incubation at room temperature for two hours, two washes with 0-1% Tween 20 borate buffered saline and one wash with 0-1 M ethanolamine buffer (pH 9-6), substrate was poured on and gently mixed (5 ml nitro blue tetrazolium 0-1% in ethanolamine buffer, 750 ,ul 10-8 mM 5-bromo-4-chloro-3-indolyl phosphate in 2:1 methanol/acetone, 200 p1l 1-0 M magnesium chloride, and 50 ml ethanolamine buffer pH 9 6 (table 2) . Baseline levels of vWF were 7-0-9 0 IU/1. After 30 minutes of hypoxia levels of vWF increased by 2-7 (0-2) IU/1, which was significantly greater than the increase in controls (1P1 (0-1) IU/1) (p<0 02). There was a synovial microvessels, however, release of platelet derived growth factor by aggregating platelets may also stimulate synovial proliferation. Platelet derived growth factor is a potent mitogen to rheumatoid synovial fibroblasts35 and in anchorage independent conditions exerts a marked proliferative action in contrast to the minimal effects of interleukin 1, tumour necrosis factor (c, interferon y, transforming growth factor ,, and epidermal growth factor.36 Furthermore there is strong evidence to suggest that platelet derived growth factor is the principal mitogen produced by rheumatoid synovium. 37 The relative importance of platelet versus macrophage derived platelet derived growth factor has yet to be established. Platelet derived growth factor is also a potent vasoconstrictor, thus vWF mediated platelet aggregation at sites of synovial endothelial cell injury could promote hypoxic reperfusion injury directly and indirectly via synovial proliferation. It might be assumed that progression of microvascular injury to occlusion would remove this source ofplatelet derived growth factor hastening 'autosynovectomy'. A clear correlation between levels of platelet derived growth factor and plasma vWF in patients following myocardial infarction suggests that vWF also reflects this aspect of endothelial injury. 38 Extrapolating from this to the clinical situation it is apparent that most patients with RA will in the course of daily life subject their joints to exercise increasing the intra-articular pressure, resulting in repeated hypoxic reperfusion insults to the synovium, creating. a vicious circle and preventing the resolution of microvascular injury and synovial inflammation. The striking clinical response of RA to bedrest accords with this view. Any alternative explanation of our data would require release of vWF from normoxic vessels beyond the synovial microvasculature. This might occur if platelets or endothelial cells were generally activated in RA, were more sensitive to stimuli releasing vWF, or these stimuli were accentuated by exercise in RA. In vivo the best known stimuli causing vWF release are agents such as adrenaline and vasopressin analogues. The theoretical effect of vasopressor stimuli releasing vWF was mitigated by the protocol stipulating 'walking for 15 minutes at their own pace' thus minimising cardiovascular workload. Moreover, 'steady state' exercise does not increase levels of vWF,37 though they do increase in response to maximal exercise or exercise to the point of 'exhaustion'.39 40 Of course, controls performed the exercise for the same duration but far exceeded the workload and distances covered by patients with RA. We cannot, however, exclude a contribution to the observed increase in vWF due to excessive stimulation or the abnormal responsiveness of endothelium or platelets in RA. Exercise clearly alters levels of vWF and at the synovial microvascular level the consequences of increased platalet aggregation would be similar.
We suggest that the data are most simply explained by radical driven synovial hypoxic reperfusion injury during exercise causing release of vWF from synovial endothelial cells. Measurement of vWF should therefore be useful in assessing the modulating actions of drugs such as gold and penicillamine on endothelial cells as well as the development of pharmacological strategies either to limit hypoxic reperfusion injury, or to promote it. Promotion may create an environment that would favour an 'autosynovectomy'.
